The FDA will allow a new dosing schedule for Eli Lilly’s Alzheimer’s drug Kisunla that could lessen a known side effect of ...

A slower ramp-up of Kisunla dosing lowers the rate of dangerous brain swelling, a risk that has made doctors reluctant to ...

The U.S. Food and Drug Administration approved changing the prescribing information for Eli Lilly's Alzheimer's drug Kisunla to allow more gradual dosing to lower the risk of a potentially dangerous ...

Biogen shares slipped on Monday after the company said it expects to take a $46 million charge in the second quarter related ...

Chris Long and his wife, Janet, were thrilled when he became the first patient at MUSC Health to receive the Alzheimer’s drug ...

Eli Lilly has won a green light from the FDA for new dosing for its Alzheimer's disease therapy Kisunla, which carries a ...

The Alzheimer’s drug Leqembi, the first medicine proven to slow the course of the disease, may be able to be given as a set of two weekly shots at home, a study from drugmaker Eisai suggests ...

Leqembi has a boxed warning about the risk of ARIA. To learn more, see the introduction of this article. Your doctor will likely order a test to check for ApoE gene status before prescribing Leqembi.

Leqembi was far from a cure, and made no claim to be one. Over 18 months, it had slowed the advance of the disease by an average of 27 percent, or by about five months, in a clinical trial of some ...

Learn about side effects, uses, cost, and more for Leqembi (lecanemab-irmb), a prescription drug that treats Alzheimer’s disease in adults.

Leqembi — sold through a partnership between Eisai Co. and Cambridge-based Biogen — is one of the first medications approved that promises to slow the speed at which Alzheimer’s erases a ...

Leqembi, an Alzheimer's drug from Biogen and Eisai, could give patients at the earliest stages of the disease more time to live normally and independent of others.